StockData

Biodesix vs Grail

BDSX and GRAL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BDSX and GRAL compare

Grail is the larger company, worth 50 times as much as Biodesix ($4.7B against $95.0M).

Biodesix grew revenue faster over the last twelve months (34.5% versus 23.1% for Grail).

Biodesix keeps more of each dollar of sales as profit, with a net margin of −27.0% compared with −237% at Grail.

Grail scores higher on the StockData Score (10 against 4 for Biodesix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBDSXGRAL
Size and price
Market cap$95.0M$4.7B
Share price$9.00$105.60
Change, 1 year13.9%26.9%
Change, 5 years−93.3%–
Beta (5Y)1.712.06
Employees334910
StockData Score
Total score410 (better)
Valuation score01 (better)
Growth score22
Performance score11
Health score16 (better)
Dividend score00
Valuation
P/S0.9× (better)28.5×
P/B10.4×1.9× (better)
FCF yield−21.3%−6.3% (better)
Growth
Revenue growth (TTM)34.5% (better)23.1%
Revenue growth, 5Y average14.2%–
Profitability
Operating margin−20.0% (better)−338%
Net margin−27.0% (better)−237%
FCF margin−19.7% (better)−179%
Return on equity−540%−16.1% (better)
Return on invested capital−61.4%−26.0% (better)
Financial health
Debt / equity5.12 (better)0.00
Interest coverage−2.5×–
Current ratio2.8510.95 (better)
Altman Z-score−6.154.03 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions41.4%87.6%
Held by insiders–11.0%
Insider net buying, 12 months$4.0M (better)−$38.0M
Short interest, % of float–20.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.